Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test
- PMID: 10443652
- DOI: 10.1210/jcem.84.8.5904
Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test
Abstract
GH deficiency (GHD) in adults must be shown by provocative testing of GH secretion. Insulin-induced hypoglycemia (ITT) is the test of choice, and severe GHD, treated with recombinant human GH replacement, is defined by a GH peak response to ITT of less than 3 microg/L. GHRH plus arginine (ARG) is a more provocative test and is as sensitive as ITT provided that appropriate cut-off limits are assumed. GH secretagogues are a family of peptidyl and nonpeptidyl GH-releasing molecules that strongly stimulate GH secretion and, even at low doses, truly synergize with GHRH. Our aim was to verify the diagnostic reliability of the hexarelin (HEX; 0.25 microg/kg, iv) and GHRH (1 microg/kg, iv) test for the diagnosis of adult GHD. To this goal, in the present study we 1) defined the normal ranges of the GH response to GHRH+HEX in a group of normal young adult volunteers (NS; n = 25; 18 men and 7 women; age, 28.5+/-0.6 yr) and in 11 of them verified its reproducibility in a second session, and 2) compared the GH response to GHRH+HEXwith that to ITT in a group of normal subjects (n = 33; 12 men and 21 women; age, 34.1+/-1.5 yr) and hypopituitaric adults with GHD (n = 19; 10 men and 9 women; age, 39.9+/-2.2 yr; GH peak <5 microg/L after ITT). The GH response to GHRH+ARG was also evaluated in all GHD and in 77 normal subjects (40 men and 37 women; age, 28.1+/-0.6 yr). The mean GH peak after GHRH+HEX in NS was 83.6+/-4.5 microg/L; the third and first percentile limits of the normal GH response were 55.5 and 51.2 microg/L, respectively). The GH response to GHRH+HEX in NS showed good intraindividual reproducibility. In GHD the mean GH peak after GHRH+HEX (2.6+/-0.7 microg/L) was similar to that after GHRH+ARG (3.6+/-1.0 microg/L), and both were higher (P < 0.001) than that after ITT (0.6+/-0.1 microg/L); the GH responses to GHRH+HEX were positively associated with those to ITT and GHRH+ARG. Analyzing individual GH responses, 100% had severe GHD after ITT (GH peak, <3 microg/L). After GHRH+HEX all GHD had GH peaks below the third percentile limit of normality appropriate for this test (i.e. 55.5 microg/L). Thirteen of 19 (68.4%) GHD subjects had GH peaks below 3 microg/L after GHRH+HEX but all 19 (100%) had GH peaks below the first percentile limit of normality (i.e. 51.2 microg/L). The GH responses to GHRH+HEX were highly concordant with those after GHRH+ARG. In conclusion, the present results define normal limits of the GH response to stimulation with low dose HEX+GHRH in normal adults and show that this test is as sensitive as ITT for the diagnosis of adult GHD provided that appropriate cut-off limits are considered.
Similar articles
-
Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.Endocrine. 2001 Jun;15(1):29-38. doi: 10.1385/ENDO:15:1:029. Endocrine. 2001. PMID: 11572322 Review.
-
Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults.J Clin Endocrinol Metab. 1998 May;83(5):1615-8. doi: 10.1210/jcem.83.5.4837. J Clin Endocrinol Metab. 1998. PMID: 9589665
-
Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test.J Clin Endocrinol Metab. 2000 Oct;85(10):3693-9. doi: 10.1210/jcem.85.10.6858. J Clin Endocrinol Metab. 2000. PMID: 11061526 Clinical Trial.
-
Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues.J Clin Endocrinol Metab. 2000 Apr;85(4):1467-72. doi: 10.1210/jcem.85.4.6538. J Clin Endocrinol Metab. 2000. PMID: 10770183
-
Diagnosis of adult GH deficiency.Growth Horm IGF Res. 2008 Feb;18(1):1-16. doi: 10.1016/j.ghir.2007.07.004. Epub 2007 Sep 4. Growth Horm IGF Res. 2008. PMID: 17766155 Review.
Cited by
-
Diagnosis of adult GH deficiency.Pituitary. 2008;11(2):121-8. doi: 10.1007/s11102-008-0110-x. Pituitary. 2008. PMID: 18404387 Review.
-
Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults.Endocrine. 2001 Jun;15(1):29-38. doi: 10.1385/ENDO:15:1:029. Endocrine. 2001. PMID: 11572322 Review.
-
Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.Endocrine. 2015 Jun;49(2):307-23. doi: 10.1007/s12020-015-0531-z. Epub 2015 Feb 4. Endocrine. 2015. PMID: 25645463 Review.
-
Primary hyperparathyroidism is associated with an impaired secretion of growth hormone but not of the other anterior pituitary hormones.J Endocrinol Invest. 2002 Mar;25(3):RC7-9. doi: 10.1007/BF03343990. J Endocrinol Invest. 2002. PMID: 11936476
-
Hexarelin: a multi-receptor peptide.J Endocrinol Invest. 2008 Jul;31(7):680. doi: 10.1007/BF03345625. J Endocrinol Invest. 2008. PMID: 18787392 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous